Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $4.6 million.

  • RedHill Biopharma's Cash & Current Investments fell 5286.21% to $4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.6 million, marking a year-over-year decrease of 5286.21%. This contributed to the annual value of $7.0 million for FY2024, which is 6624.66% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Cash & Current Investments is $4.6 million, which was down 5286.21% from $6.0 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Cash & Current Investments peaked at $76.0 million during Q1 2021, and registered a low of $4.6 million during Q2 2025.
  • In the last 5 years, RedHill Biopharma's Cash & Current Investments had a median value of $22.9 million in 2021 and averaged $26.4 million.
  • As far as peak fluctuations go, RedHill Biopharma's Cash & Current Investments skyrocketed by 11568.86% in 2021, and later crashed by 7572.02% in 2023.
  • Over the past 5 years, RedHill Biopharma's Cash & Current Investments (Quarter) stood at $29.5 million in 2021, then decreased by 23.35% to $22.6 million in 2022, then dropped by 8.33% to $20.7 million in 2023, then tumbled by 70.84% to $6.0 million in 2024, then decreased by 23.35% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q2 2025, $6.0 million for Q4 2024, and $9.8 million during Q2 2024.